InnoMedica’s Nanofactory ensures continuous manufacturing in compliance with Good Manufacturing Practice (GMP) — from the incoming raw material inspection to the sterile, injectable final product. This integrates the entire value chain for the development of innovative liposomal medications for clinical use under one roof.
The Nanofactory in Marly, near Fribourg, is a key success factor for InnoMedica and a strong commitment to the production base in Switzerland. Research and development, modular cleanroom production, quality control, as well as the filling and provision of finished vials, are closely integrated both spatially and organizationally. Since the Swissmedic certification of the first cleanroom in 2014, the expansion with cleanroom II in 2021, and the approval for large-scale production in 2023, the Nanofactory has become a robust manufacturing facility capable of handling larger production volumes in the event of market approval. The multi-purpose design allows for the flexible use of cleanrooms for the production of various drugs.
The development of liposomal nanomedicines requires close collaboration across all departments. Research and development generate new prototypes and advance the product pipeline. Quality control develops the analytical methods necessary to ensure product quality. Manufacturing translates prototypes into robust GMP processes and gradually scales them for clinical trials and potential market launch.
This cross-departmental collaboration creates synergies that enable efficient and consistent implementation of innovations into routine pharmaceutical production. The knowledge of all production steps remains fully in-house — a key advantage for the continuous development of the technology platform and its adaptation to specific medical applications.
